Journal
CLINICAL BREAST CANCER
Volume 13, Issue 4, Pages 223-232Publisher
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clbc.2013.04.001
Keywords
Basal molecular subtype; Her2-overexpressing breast cancer; Resistance; Trastuzumab (Herceptin)
Categories
Funding
- University of California Los Angeles Clinical and Translational Science Institute Clinical Scholars Program (National Institutes of Health/National Center for Advancing Translational Science UCLA Clinical and Translational Science Institute) [UL1TR000124]
- Cedars Sinai Medical Center Clinical Scholars Program (CSMC CTSI Whiting-Eigler Grant)
- David Salomon Breast Cancer Research Fund
- National Institutes of Health [CA151610]
- Avon Foundation [02-2010-068]
Ask authors/readers for more resources
Human epidermal growth factor receptor 2-overexpressing (HER2+) breast cancer occurs in 20% to 25% of cases and is associated with poor prognosis. Trastuzumab (Herceptin; Genentech, South San Francisco, CA) is a monoclonal antibody targeting the HER2 extracellular domain that has been shown to significantly reduce relapse rates. However, some patients with HER2+ tumors do not respond to Herceptin, and 60% to 85% of patients with HER2+ metastatic breast cancer acquire resistance within a short time period. In this review, we discuss proposed mechanisms of action of trastuzumab and trastuzumab resistance and various drugs that have been developed to overcome drug resistance. We introduce the basal molecular subtype as a predictor of increased risk in HER2+ breast cancer and a possible alternative cause of drug resistance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
